Early-stage Node-negative (T1-T2N0) Anal Cancer Treated with Simultaneous Integrated Boost Radiotherapy and Concurrent Chemotherapy.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

To report clinical outcomes of a consecutive series of patients with early-stage (T1-T1N0) anal cancer treated with intensity-modulated radiotherapy (IMRT) and a simultaneous integrated boost (SIB) approach similarly to the RTOG 05-29 trial.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Anticancer Res.

Title: Anticancer research

ISSN (Electronic): 1791-7530

ISSN (Print): 0250-7005

Publication date (Electronic): Apr 2016

Volume: 36

Issue: 4

Affiliations

[1 ] Department of Oncology-Radiation Oncology, University of Turin, Turin, Italy pierfrancesco.franco@unito.it.

[2 ] Department of Oncology-Radiation Oncology, University of Turin, Turin, Italy.

[3 ] Department of Surgical Sciences, University of Turin, Turin, Italy.

[4 ] Department of Medical Sciences, University of Turin, Turin, Italy.

[5 ] Department of Medical Imaging and Radiotherapy-Radiation Oncology, City of Health and Science Hospital, Turin, Italy.

[6 ] Oncological Centre for Gastrointestinal Neoplasm, Medical Oncology 1, City of Health and Science Hospital, Turin, Italy.

Article

Publisher Item ID: 36/4/1943

PubMed ID: 27069184

SO-VID: 789dfef3-d910-4c0a-9ab0-1ee1d33d37ca

History

Keywords: acute toxicity,volumetric-modulated arc therapy,radiotherapy,concomitant radiochemotherapy,VMAT,IMRT,Anal cancer

Data availability:

Keywords: acute toxicity, volumetric-modulated arc therapy, radiotherapy, concomitant radiochemotherapy, VMAT, IMRT, Anal cancer

Comments

Comment on this article

Cited by 5

See all cited by